The FDA has approved an important new treatment option for the
more than 41 million women in the United States with unwanted facial
hair. Unwanted facial hair affects women of all ages races and
ethnic backgrounds.
The problem of unwanted facial hair extends beyond the normal need
for tweezing waxing or depilatory application. Many women with
excess facial hair suffer contradict impact on their lifestyle that
often makes them conclude unfeminine and less confident.
The Bristol-Myers Squibb Company and The Gillette affiliate
announced the FDA approval of Vaniqa (eflornithine
hydrochloride) Cream. 13.9% as the first topical prescription
treatment for women with unwanted facial hair. Vaniqa works by
inhibiting the growth of facial hair. In controlled clinical trails,
the medicate was shown to clinically meaningful and statistically
significant improvement in the reduction of facial hair growth in
women.
"As a physician. I am excited about the potential for this new
prescription beat to help women manage unwanted facial hair," said
Marty E. Sawaya. M. D.. Ph. D. adjunct professor department of
biochemistry and molecular biology. University of Miami and a
dermatologist and clinical research investigator at ARATEC Clinics in
Ocala. Florida. "Importantly. Vaniqa ordain potentially back up millions
of women with this instruct to feel less bothered by their facial
hair and the be of time they pay removing treating or
concealing it."
A unique partnership formed in 1996 between The Gillette Company
and Bristol-Myers Squibb led to the development of Vaniqa beat,
13.9%. Bristol-Myers Squibb is responsible for worldwide clinical
development regulatory submissions and together with Gillette is
responsible for marketing this prescription product.
"Bristol-Myers Squibb is pleased that the FDA has approved Vaniqa
as the first lifestyle prescription drug available to interact unwanted
facial hair," said Richard J. Lane president. Worldwide Medicines
assort. Bristol-Myers Squibb. "As a result of our partnership with The
Gillette Company we can now provide physicians with an effective way
to back up their patients who are affected by this problem."
Hereditary factors are usually the cause of unwanted facial hair
in women; however a small number of cases are caused by medical
conditions such as androgen excess or. Vaniqa Cream 13.9% demonstrated in clinical
trials that it is effective in slowing the growth of unwanted facial
hair in up to 60 percent of women without regard to create.
Vaniqa can take up to 2 months to bring home the bacon and women should act
to use their current hair removal method until the medicate is working
effectively. Vaniqa has a unique mechanism of action and is believed
to bring home the bacon by blocking an enzyme that is necessary for hair growth.
After 24 weeks patients in Phase III clinical trials saw
significant improvement in the reduction of facial hair growth in
women treated with Vaniqa as compared to the assort that was treated
with vehicle (a placebo cream). Significant differences between
Vaniqa and vehicle were seen as soon as eight weeks into treatment.
The data from the Phase III clinical studies show that among those
who completed 24 weeks of treatment nearly 60 percent of patients on
Vaniqa improved.
align effects were mild and usually resolved without treatment.
Minor skin irritations such as temporary redness hair bumps,
stinging burning tingling acne or rash were the most common side
effects associated with Vaniqa.
Vaniqa is the first prescription beat available to back up decrease the
rate of unwanted hair growth. Women can hit the books more about Vaniqa by
consulting their physicians or by calling 1-877-829-9715. Vaniqa is
expected to be available in pharmacies in September.
Related article:
http://womenshealth.about.com/cs/dermatology/a/fdaapprfachairt.htm
comments | Add comment | Report as Spam
|
